Rob is a Research Associate with more than 12 years of research experience in malaria. His core research interests focus on understanding the biology underlying novel antimalarial drug targets and mechanisms of drug resistance using a range of cell physiology, biochemistry and molecular genetics techniques. His current research focuses on the Plasmodium falciparum acetyl CoA synthetase (PfAcAS), a novel drug target implicated in protein acetylation and the epigenetic regulation of…
The current gold standard malaria treatments are artemisinin combination therapies (ACTs), but unfortunately, artemisinins are threatened by growing resistance. Imran employs cutting-edge cell and molecular biology techniques to understand the underlying mechanisms of Pfcoronin– and Pfkelch13-mediated artemisinin resistance. In collaboration with several other lab members and partners, Imran is also involved in assessing the potential impacts of specific Pfkelch13 and Pfcoronin polymorphisms in malaria parasites from Senegal, where ACTs are…